Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Net Margin: 2022-2025

Historic Net Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -349.30%.

  • bioAffinity Technologies' Net Margin fell 26417.00% to -349.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -217.50%, marking a year-over-year decrease of 12734.00%. This contributed to the annual value of -96.56% for FY2024, which is 21685.00% up from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' Net Margin is -349.30%, which was down 9.20% from -319.88% recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Net Margin ranged from a high of 7.67% in Q2 2022 and a low of -427,778.96% during Q3 2022.
  • Its 3-year average for Net Margin is -16,119.96%, with a median of -143.53% in 2025.
  • Data for bioAffinity Technologies' Net Margin shows a peak YoY increase of 42,701,145bps (in 2023) and a maximum YoY decrease of 882,403bps (in 2023) over the last 5 years.
  • Over the past 4 years, bioAffinity Technologies' Net Margin (Quarterly) stood at -71,380.35% in 2022, then surged by 7,127,313bps to -107.22% in 2023, then tumbled by 2,717bps to -134.40% in 2024, then slumped by 26,417bps to -349.30% in 2025.
  • Its Net Margin stands at -349.30% for Q3 2025, versus -319.88% for Q2 2025 and -143.53% for Q1 2025.